Teva signs deal for two FDA-approved biosimilars
Key points
- eva signed an agreement with Samsung Bioepis for U.S. commercialization rights to two FDA-approved biosimilars targeting inflammatory and autoimmune conditions.
- Teva will make an upfront payment over three years, with additional payments tied to launches and sales milestones, while both companies will share commercialization profits.
- Teva expects the transaction to close by the end of 2026, expanding its U.S. biosimilars portfolio under its Pivot to Growth strategy.
Teva Pharmaceutical Industries (NYSE:TEVA) signed an agreement with Samsung Bioepis to commercialize two FDA-approved biosimilars in the United States, expanding its immunology portfolio.
The agreement covers ETICOVO (etanercept-ykro), referencing Enbrel, and infliximab-abda, referencing Remicade, both targeting inflammatory and autoimmune conditions.
"This agreement strengthens our collaboration with Samsung Bioepis and will expand our U.S. immunology portfolio with two additional biologic treatment options," said Teva President and Chief Executive Officer Richard Francis.
Teva will obtain ETICOVO commercialization rights at closing and infliximab-abda rights in the third quarter of 2027, while Samsung Bioepis retains manufacturing and regulatory oversight.
The transaction is expected to close by the end of 2026, subject to regulatory approvals, with Teva making payments over three years and potentially paying additional milestones linked to launches and sales.
ETICOVO received FDA approval in 2019 but is not currently marketed in the United States, and Teva has not announced its planned commercial launch date.
The agreement follows the companies' 2025 U.S. collaboration on EPYSQLI and their 2026 arrangements covering OPUVIZ in Canada and up to six additional biosimilar candidates.
